85 completed, 14 unknown, 13 terminated, 10 recruiting. 134 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 134 | Completed 85, Unknown 14, Terminated 13, Recruiting 10, Not yet recruiting 6, Withdrawn 6 |
Follow Urinary Bladder, Overactive: new trials by email Literature Review of Urinary Bladder, Overactive trials Research Report on Urinary Bladder, Overactive
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Defining the Safety and Efficacy of POSterIor Tibial NeRve StimulatiON in Children Urgent PC - Overactive Bladder, Overactive Bladder Syndrome | Phase 4 | Not yet recruiting | Chi Dang Hornik | 50 | 2027-04-01 | 2026-06-17 |
| Behavioral and/or Mirabegron to Treat Urinary Symptoms in Parkinson Disease mirabegron, Exercise-based behavioral therapy - Overactive Bladder, Parkinson Disease | Phase 4 | Not yet recruiting | VA Office of Research and Development | 146 | 2026-11-09 | 2026-10-27 |
| Burden and Efficacy of Anticholinergic vs Mirabegron in Overactive Bladder - A Randomized Controlled Study Solifencin, Mirabegron - Overactive Bladder (OAB) | Phase 4 | Not yet recruiting | Universidade do Porto | 208 | 2026-07-01 | 2026-07-17 |
| Pilot Deprescribing of Antimuscarinic Overactive Bladder Medications in Parkinson Disease Overactive bladder antimuscarinic deprescribing - Parkinson Disease (PD) | Phase 4 | Not yet recruiting | Corporal Michael J. Crescenz VA Medical Center | 20 | 2026-06-01 | 2026-06-04 |
| The Combined Effect of Intravesical Botox Injections and HoLEP Surgery in Treating Benign Prostatic Hyperplasia and Overactive Bladder Intravesical Botox injection - Benign Prostatic Hyperplasia, Overactive Bladder | Phase 4 | Withdrawn | University Hospitals Cleveland Medical Center | 2026-06-01 | 2025-09-05 | |
| A Randomized, Placebo-controlled Trial of Nitrous Oxide During In-office Bladder Botox Injections Pro-Nox Nitrous Oxide/Oxygen Delivery System, Standard Care for Bladder Botox Injection, Sham Mask - Overactive Bladder, Neurogenic Bladder | Phase 4 | Not yet recruiting | TriHealth Inc. | 96 | 2026-02-01 | 2026-02-04 |
| Low-intensity Shockwave Therapy Versus Solifenacin for the Treatment of Overactive Bladder in Women Low intensity shockwave therapy, Oral Solifenacin succinate 5 mg - Overactive Bladder (OAB), Urge Incontinence | Phase 4 | Recruiting | Mansoura University | 70 | 2025-11-11 | 2026-03-16 |
| Randomized Controlled Trial Comparing Low Dose Tadalafil Versus Solifenacin For Management of Overactive Bladder in Women: Multicenter Egyptian National Study Tadalafil 5 mg, Solifenacin 5mg - Overactive Bladder (OAB), Overactive Bladder Syndrome | Phase 4 | Recruiting | Mansoura University | 480 | 2025-09-01 | 2026-02-18 |
| Methenamine Hippurate Following Intradetrusor OnabotulinumtoxinA Injection Methenamine Hippurate, Typically prescribed oral antibiotic prophylaxis - Overactive Bladder (OAB), Urinary Tract Infection (Diagnosis) | Phase 4 | Recruiting | Women and Infants Hospital of Rhode Island | 164 | 2025-08-01 | 2026-08-19 |
| Prophylactic Analgesia for Bladder Botox Injections Phenazopyridine, 1% lidocaine with sodium bicarbonate - Urinary Incontinence, Urinary Incontinence, Urge | Phase 4 | Withdrawn | Montefiore Medical Center | 2025-07-01 | 2025-07-18 | |
| Effect of Vaginal Estrogen on Alterations in the Urine Microbiome of Menopausal Women With Overactive Bladder 17β-estradiol 10 mcg - Overactive Bladder (OAB), Menopause | Phase 4 | Completed | Mahidol University | 30 | 2025-06-27 | 2026-02-09 |
| Optimal Intravesical Lidocaine Volume for Pain Relief During Office Intra-detrusor Onabotulinum Toxin a Injections Lidocaine 2% without vessel constrictor - Overactive Bladder, Overactive Bladder Syndrome | Phase 4 | Not yet recruiting | University of Louisville | 36 | 2024-12-01 | 2024-11-19 |
| Efficacy of Vaginal 17β-Estradiol on the Urinary Storage Symptoms in Postmenopausal Women vaginal 17 beta-estradiol, Placebo, Behavioral modifications - Lower Urinary Tract Symptoms, Female Genitourinary Disease | Phase 4 | Completed | Mahidol University | 86 | 2024-04-08 | 2025-04-20 |
| Bladder Botox UTI Antibiotic Prophylaxis Nitrofurantoin 100 MG - Overactive Bladder, Bladder Pain Syndrome | Phase 4 | Recruiting | Walter Reed National Military Medical Center | 100 | 2024-04-04 | 2025-02-19 |
| Comparing Treatments for Refractory Overactive Bladder: Bladder Denervation vs Botulinum Toxin Injections Selective Bladder Denervation via Radiofrequency Ablation, Intravesical Onabotulinum Toxin A Injection - Overactive Bladder Syndrome, Refractory Overactive Bladder | Phase 4 | Completed | Bagcilar Training and Research Hospital | 60 | 2023-02-01 | 2025-02-19 |
| A Pilot Study to Assess Effects of Self-Administered Nitrous Oxide (SANO) on Urodynamic Study (UDS) Parameters Self-Administered Nitrous Oxide, Oxygen - Lower Urinary Tract Symptoms | Phase 4 | Completed | Beth Israel Deaconess Medical Center | 19 | 2023-01-10 | 2026-03-12 |
| Prophylactic Antibiotic Administration for Bladder OnabotulinumtoxinA Injection Single-Dose Antibiotic, Multi-Dose Antibiotic - Overactive Bladder, Overactive Bladder Syndrome | Phase 4 | Completed | The Cleveland Clinic | 100 | 2022-12-06 | 2024-01-02 |
| TReating Incontinence for Underlying Mental and Physical Health Tolterodine Tartrate ER, Mirabegron, Placebo - Urinary Incontinence, Urge, Urinary Incontinence | Phase 4 | Recruiting | University of California, San Francisco | 270 | 2022-10-04 | 2026-03-06 |
| Mirabegron Combined With Behavioral Intervention for Overactive Bladder：a Prospective Multicenter Randomized Controlled Clinical Study mirabegron - Overactive Bladder | Phase 4 | Unknown | Peking Union Medical College Hospital | 600 | 2022-07-15 | 2022-07-11 |
| Procedural Discomfort Related to Number of Intradetrusor Botox Injections Intradetrusor Botox Injections - Overactive Bladder | Phase 4 | Completed | The Methodist Hospital Research Institute | 108 | 2022-07-07 | 2025-04-13 |
Showing 20 of 134. Sign in to see all of them.
Urinary Incontinence, Urge (24) · Urinary Incontinence (18) · Prostatic Hyperplasia (9) · Lower Urinary Tract Symptoms (8) · Parkinson Disease (7) · Nocturia (6) · Urinary Bladder, Neurogenic (5) · Cystitis, Interstitial (3) · Urinary Tract Infections (3) · Agnosia (2) · Pain (2) · Urinary Incontinence, Stress (2) · Urination Disorders (2) · Xerostomia (2)
Female Urogenital Diseases and Pregnancy Complications (134) · Male Urogenital Diseases (134) · Pathological Conditions, Signs and Symptoms (134) · Signs and Symptoms (134) · Urogenital Diseases (134) · Urological Manifestations (134) · Female Urogenital Diseases (133) · Urinary Bladder Diseases (133) · Urologic Diseases (133) · Lower Urinary Tract Symptoms (126) · Urination Disorders (35) · Nervous System Diseases (19) · Urinary Incontinence (17) · Neurologic Manifestations (10) · Central Nervous System Diseases (9)
Solifenacin Succinate (31) · mirabegron (25) · Tolterodine Tartrate (14) · Botulinum Toxins, Type A (13) · fesoterodine (13) · Tamsulosin (7) · darifenacin (5) · trospium chloride (5) · Lidocaine (4) · oxybutynin (4) · Estrogens, Conjugated (USP) (3) · Anti-Bacterial Agents (2) · Estradiol (2) · Estrogens (2) · Idoxuridine (2)
Astellas Pharma Inc (9) · Allergan (7) · Pfizer (7) · Samsung Medical Center (6) · Novartis (4) · Astellas Pharma Global Development, Inc. (3) · KYU-SUNG LEE (3) · Mackay Memorial Hospital (3) · Mansoura University (3) · Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (3) · Uroplasty, Inc (3) · Walter Reed National Military Medical Center (3) · Barrie Urology Associates (2) · Loyola University (2) · Mahidol University (2)
United States (69) · South Korea (20) · Canada (13) · Taiwan (8) · United Kingdom (8) · Turkey (Türkiye) (7) · Germany (6) · Italy (6) · Czechia (5) · Egypt (5) · Norway (5) · Poland (5) · Spain (5) · Sweden (5) · France (4)
Kyu-Sung Lee, Ph.D (7) · Hui-Hsuan Lau, MD (3) · Alan Wolfe, PhD (2) · Joseph A Zadra, MD CM FRCSC (2) · Rose Khavari, MD (2) · Ahana Gaurav (1) · Ahmed A Shokeir, professor of urology (1) · Ahmed Elhefnawy (1) · Alexandriah Alas, MD (1)
PMID 37160401, PMID 35881009, PMID 37811598, PMID 10435146, PMID 10775736, PMID 12811491, PMID 15712851, PMID 15767530, PMID 17049716, PMID 17132474, PMID 17187655, PMID 17618768, PMID 17983434, PMID 18499184, PMID 18811599, PMID 19070418, PMID 19912183, PMID 19930331, PMID 20025017, PMID 20025020, PMID 20035977, PMID 20419366, PMID 20690893, PMID 20860020, PMID 20952013, PMID 21175373, PMID 21235700, PMID 21256571, PMID 21489081, PMID 21532512, PMID 21684773, PMID 21718275, PMID 22464310, PMID 22622849, PMID 22674493, PMID 22840868, PMID 23036134, PMID 23460503, PMID 23608668, PMID 23973522, PMID 24415559, PMID 24552358, PMID 24792229, PMID 24898471, PMID 25363606, PMID 25401784, PMID 26364180, PMID 26724409, PMID 27350947, PMID 28067745
2008 (1), 2015 (1), I01RD000466 (1), R01AG075471 (1), R33AG086944 (1)